SELLAS Life Sciences Group, Inc. (SLS)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about SELLAS Life Sciences Group, Inc. (SLS)
Go deeper and ask any question about SLS
Company Performance
Current Price
as of Sep 13, 2024$1.32
P/E Ratio
N/A
Market Cap
$84.92M
Description
SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S and nelipepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.
Metrics
Overview
- HQNew York, NY
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerSLS
- Price$1.32-0.75%
Trading Information
- Market Cap$84.92M
- Float99.57%
- Average Daily Volume (1m)473,317
- Average Daily Volume (3m)833,068
- EPS-$0.92
Company
- RevenueN/A
- Rev Growth (1yr)N/A
- Net Income-$7.47M
- Gross MarginN/A
- EBITDA MarginN/A
- EBITDA-$7.62M
- EV$60.03M
- EV/RevenueN/A
- P/EN/A
- P/SN/A
Documents
SEC Filings
Factset Street Account